INTRODUCTION:
More than two-thirds of the world's population live in low-income countries, where health priorities are very different from those in more affluent parts of the world. Relative to people living in wealthy nations, the most impoverished 20% of the world's population is 9 times more likely to die of infectious diseases and 10 times more likely to die in childhood. 1 Developed country like Germany has unique pattern of diseases, where due to increasing life expectancy chronic diseases account for 92% of all deaths. The Federal Government in Germany has taken steps to establish German Centers for Health Research to pool research into a number of particularly important common diseases in Germany. The developing country like India has its own problems because of wide gap between the rich and poor population. It has diseases of both developing and developed countries.
On an international level, the Global Forum for Health Research has estimated that less than 10% of health research spending is directed toward diseases or conditions that account for 90% of the global burden of disease, a phenomenon referred to as the -10/90 gap.‖ These numbers suggest that many common conditions or diseases are not being adequately studied.
Numerous studies have found that the drug development process is highly expensive and that these costs have trended significantly upward for decades. The clinical approval success rate in the United States was 16% to 19 % during both the 1993-1998 and the 1999-2004 sub periods. However success rates varied significantly by therapeutic class. Clinical approval success rates varied from 8% for CNS drugs to 24% for systemic anti-infectives. 1 Many of these new trials are being performed in geographical areas of political and economic instability and unprecedented health care crises and where subjects are readily accessible. Drug companies' apparent ease of accessibility to such areas raises questions about the unequal social contexts in which research is being performed and about how conditions of inequality are at present facilitating a global proliferation of pharmaceutical drug trials.
After taking a review of all the above information it is very important to know the correlation between disease burdens, number of clinical trials done and success rates of these trials. This study will help to gain following understanding of a much sought co-relation between disease burden and number of clinical trials done. Looking at the increasing number of clinical trials done in India It will help to answer the important question do we really need these trials, is it ethical, does it fall in line with typical health situation in India -a country with disease of both developing and developed countries? It will also help to understand which disease areas need more clinical research in a developed country like Germany with increasing aging population and subsequent increase in age related diseases. Finally this study will offer some suggestions to a unique problem of decreasing success of clinical trials.
OBJECTIVES:
 
MAIN OUTCOME MEASURES:
Countries: Germany and India; Time Period: 2005-2010.  Number of trials and randomized subjects for each category of disease in the global burden of disease taxonomy.  Disease burden analysis.  Phase-wise trial success rates for each category of disease.
MATERIALS AND METHODS:
We compared 2005-2010 Global Burden of Disease data for Germany, India and number of clinical trials from clinicaltrials.gov database done in the same period. 4, 5 To assess the burden of disease, both mortality and morbidity must be taken into account. We used disability-adjusted life year (DALY) as a measure of burden of disease. The DALY is a time-based measure that combines years of life lost due to premature mortality and years of life lost due to time lived in health states of less than ideal health.
Mortality is based only on the number of deaths, whereas as DALYs for a disease or health condition are calculated as the sum of the Years of Life Lost (YLL) due to premature mortality in the population and the Years Lost due to Disability (YLD) for people living with the health condition or its consequences. (WHO Reference)
We used a careful 2-step process for data search of this study. First we conducted an extensive search from GBD database (Reference) for the top 25 diseases for Germany and India in the period from 2005 to 2010. As a second step for those top 25 diseases for Germany and India we did search to determine the number of trials specifically for Germany and India from clinicaltrials.gov database in the period of 2005 to 2010. DALY values were then expressed as % DALY based on total DALY (All cause), on the similar basis clinical trial for each of the 25 diseases were expressed as % clinical trials based on total clinical trial for all 25 diseases for ease of analysis.
Correlation coefficient R was then calculated for % DALY and % Clinical Trials for 2005 and 2010. P value was also determined to understand the significance of the result. Table 1 shows the values of % of DALYS and % Clinical trials done in Germany in 2005 for top 25 diseases in Germany. 4, 5 This table clearly shows that Non communicable diseases (87.9%), Cardiovascular and circulatory diseases (19.9%) and Neoplasms (17.8%) are the top 3 diseases in this period. Table 1 shows that in this period there is a good match between % DALYs and % Clinical trials. Table 2 shows that there is not a perfect match between % clinical trials done in this period and DALYs. India needs more trials on communicable, neonatal and nutritional diseases, also on diseases like diarrhea, respiratory infections and other common infections.
RESULTS:

Graph 1: Correlation between % DALYs and % Clinical Trials for Germany 2005
Graph 2 shows the correlation between % DALYs and % Clinical trials. We calculated Pearson Correlation Coefficient and the value of R is 0.6811. This shows a moderate positive correlation, which means there is a tendency for high % DALY variable scores go with high % Clinical Trial variable scores (and vice versa). P Value from Pearson (R) is 0.000178. The result is significant at p < 0.05. Graph 3 shows the correlation between % DALYs and % Clinical trials. We calculated Pearson Correlation Coefficient and the value of R is 0.96. This shows a strong positive correlation, which means that high % DALY variable go with high % Clinical trial variable scores (and vice versa). P Value from Pearson (R) is < 0.00001. The result is significant at p < 0.05. Table 4 shows the values of % of DALYS and % Clinical trials done in India in 2010 for top 25 diseases in India. 4, 5 Implications for policymakers and the future: India like most of the developing countries cannot fully afford to support medical research. In addition, the pharmaceutical industry may be reluctant to sponsor trials in the developing world because the prospects for profit are limited, even if effective treatments are developed. Not for profit organizations and medical institutes may also have difficulty supporting such research on their own. They may have difficulty in setting priorities and often prefer to offer practical help rather than foster research. Despite these limitations, the major health problems of the developing world cannot be set aside. Their consequences also affect the developed world. Success can often be obtained with limited funds. Many diseases in India coexist in vulnerable patient groups, and treatment or prevention of one disease may have a major effect on another (for example, nutritional disorders, infections and maternal-neonatal disorders). Seemingly expensive interventions can become affordable if there is strong political will and collaboration with the industry. The pace of clinical research is already at the top as India has become major destination for global clinical research. Still there is a need for more international support and focus on country specific diseases -local diseases and disorders‖ instead of fostering just another form of colonization. It is certain that Indian researchers should have a meaningful say in setting research priorities, and outside support should help develop sustainable local research capacity.
